2024 universal registration document

5. 2024 Consolidated Financial Statements

Justification of Assessments - Key Audit Matters

In accordance with the requirements of Articles L. 821-53 and R. 821-180 of the French Commercial Code (Code de commerce) relating to the justification of our assessments, we inform you of the key audit matters relating to risks of material misstatement that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period, as well as how we addressed those risks.

These matters were addressed in the context of our audit of the consolidated financial statements as a whole and in forming our opinion thereon, and we do not provide a separate opinion on specific items of the consolidated financial statements.

Valuation of goodwill and indefinite-life brands

See Notes 7.1 "Goodwill", 7.2 "Other intangible assets", 7.3 “Impairment tests of intangible assets” and 4 “Other operating income and expenses”, to the consolidated financial statements

Risk identified Our response

Risk identified

As at December 31, 2024, the net book value of goodwill and indefinite-life brands amounted respectively to M€ 13,382 and M€ 2,737 (representing a total of 29% of assets) as described in Note 7 to the consolidated financial statements.

These assets are subject to an impairment test whenever an adverse event occurs, and at least once a year, in order to verify that their book value does not exceed their recoverable value.

The recoverable values of each cash-generating unit (CGU) are determined based on the discounted projections of future operating cash flows over a ten-year period (the necessary period for the strategic positioning of an acquisition) and a terminal value. The assumptions taken into account in the valuation of the recoverable value are described in Note 7.3 and mainly relate to:

  • the increase in revenue and margin rate;
  • an infinite growth rate for calculating the terminal value, and
  • discount rates based on the weighted average cost of capital, including a country risk premium if necessary.

The impairment tests carried out in 2024 showed an impairment of M€ 48,4 on goodwill and an impairment of M€ 1,6 on brands.

We considered the valuation of these assets to be a key audit matter given their relative proportion in the consolidated financial statements, and because determining their recoverable value requires significant judgment from Management in order to determine future cash flow projections and the key assumptions used.

Our response

We obtained an understanding of Management's methodology for conducting impairment tests and sensitivity analyses.

We evaluated these, especially by reconciling them with our own sensitivity analyses, in order to define the nature and scope of our work.

We assessed the quality of the budgeting and forecasting processes.

For the impairment tests of the assets considered the most sensitive, our work consisted, in particular, in assessing the reasonableness of the main estimates, and more specifically in:

  • assessing the consistency of revenue and margin rate projections with your Group's past performance and the economic and financial context in which your Group operates;
  • corroborating the future growth rates used with the performance analyses of the global cosmetics market, taking into account the specificities of the local markets and distribution channels in which your Group operates;
  • analyzing the discount rates applied to future cash flows by comparing the parameters used with external references, long-term growth rates and royalty rates by including valuation experts in our team;
  • examining sensitivity analyses against Management’s key assumptions and against our own analyses.

We assessed the appropriateness of the information given in the notes to the consolidated financial statements.